Valuation: Mymetics Corp

Market Cap 4L 4L 4L 3L 6L 4.21Cr 6L 42.68L 16.67L 2.08Cr 16.47L 16.12L 7.18Cr P/E 2021
-1.86x
P/E 2022 -1.77x
Enterprise Value 7.21Cr 6.34Cr 5.9Cr 5.42Cr 10Cr 691.65Cr 10Cr 70Cr 27Cr 341.53Cr 27Cr 26Cr 1.18TCr EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 58 19/11/2012
Change 5-day change 1-year change 3-year change Capi.($)
-11.43%+44.21% - - 45
-1.82%+5.03%+56.71%+66.69% 5.73TCr
-0.27%+5.74%+40.26%+80.17% 5.5TCr
-1.94%-1.16%+3.96%+418.53% 2.32TCr
+2.09%-0.19%-18.45%-12.40% 2.26TCr
-1.13%+4.54%+22.73%-8.06% 2.05TCr
+1.57%+3.30%+27.41%-29.07% 1.76TCr
-0.10%+5.57%+38.63%+565.16% 1.57TCr
+5.29%0.00%+185.09%+332.66% 1.45TCr
+0.88%+0.87%+26.19%+185.79% 1.39TCr
Average -0.67%+1.62%+42.50%+177.72% 2.67TCr
Weighted average by Cap. -0.08%+1.93%+40.52%+138.37%

Financials

2021 2022
Net sales 4L 4L 4L 3L 6L 4.12Cr 6L 41.83L 16.34L 2.04Cr 16.14L 15.79L 7.04Cr 10.28L 9L 8L 8L 14.51L 9.86Cr 14.7L 99.99L 39.05L 4.87Cr 38.59L 37.76L 17Cr
Net income -47.3L -41.58L -38.71L -35.55L -66.75L -45Cr -67.63L -4.6Cr -1.8Cr -22Cr -1.78Cr -1.74Cr -77Cr -48.05L -42.24L -39.32L -36.11L -67.81L -46Cr -68.7L -4.67Cr -1.83Cr -23Cr -1.8Cr -1.76Cr -79Cr
Net Debt 6.71Cr 5.9Cr 5.49Cr 5.04Cr 9.47Cr 643.48Cr 9.59Cr 65Cr 25Cr 317.74Cr 25Cr 25Cr 1.1TCr 7.17Cr 6.3Cr 5.87Cr 5.39Cr 10Cr 687.44Cr 10Cr 70Cr 27Cr 339.45Cr 27Cr 26Cr 1.17TCr
Logo Mymetics Corp
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
-